Alpha-mannosidosis, infantile form is a rare genetic disorder caused by a deficiency of the enzyme alpha-mannosidase. This enzyme is responsible for breaking down complex sugars in the body. When the enzyme is deficient, these sugars accumulate in the body, leading to a variety of symptoms including developmental delays, hearing loss, skeletal abnormalities, and organ dysfunction.

The symptoms of Alpha-mannosidosis, infantile form, can vary from person to person, but may include:

-Delayed development
-Intellectual disability
-Growth retardation
-Coarse facial features
-Hearing loss
-Cataracts
-Liver and spleen enlargement
-Joint stiffness
-Gait abnormalities
-Seizures
-Behavioral problems
-Frequent infections

Alpha-mannosidosis, infantile form is caused by mutations in the MAN2B1 gene. This gene provides instructions for making an enzyme called alpha-D-mannosidase. This enzyme is involved in the breakdown of complex sugar molecules called glycoproteins. Mutations in the MAN2B1 gene reduce or eliminate the activity of alpha-D-mannosidase, which leads to the buildup of glycoproteins in cells throughout the body. This buildup causes the signs and symptoms of alpha-mannosidosis, infantile form.

The treatments for Alpha-mannosidosis, infantile form, include enzyme replacement therapy, bone marrow transplantation, and gene therapy. Enzyme replacement therapy involves the intravenous administration of a recombinant form of the deficient enzyme, which helps to reduce the accumulation of glycoproteins in the body. Bone marrow transplantation is a procedure in which healthy stem cells from a donor are transplanted into the patient, which can help to reduce the symptoms of the disease. Gene therapy is a newer form of treatment that involves the introduction of a healthy gene into the patient's cells, which can help to correct the genetic defect that causes Alpha-mannosidosis.

1. Alpha-mannosidosis is an inherited disorder caused by a mutation in the MAN2B1 gene.

2. It is inherited in an autosomal recessive pattern, meaning both parents must carry the mutated gene for a child to be affected.

3. It is more common in certain ethnic groups, such as Ashkenazi Jews, Italians, and Finns.

4. It is also more common in males than females.

5. Exposure to certain environmental toxins, such as lead, may increase the risk of developing Alpha-mannosidosis.

There is no cure for Alpha-mannosidosis, infantile form. However, there are medications that can help manage the symptoms. These include enzyme replacement therapy, which helps replace the missing enzyme, and medications to help manage the symptoms, such as pain medications, anticonvulsants, and antibiotics. Additionally, physical and occupational therapy can help improve mobility and quality of life.